BRD-K98645985
Based on 4 publication(s) in Google Scholar
BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC50 of ~2.37 μM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.70%
- No. CAS: 1357647-78-9
- Fòrmula: C33H43N5O4
- Peso molecular:573.73
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-119374
BRM/BRG1 ATP Inhibitor-1BRM/BRG1 ATP Inhibitor -
HY-144835
CamibirstatBRG1/BRM ATPase Inhibitor -
HY-128359
ACBI1SMARCA2/SMARCA4/PBRM1 Degrader -
HY-145388
AU-15330Anticancer Reagent -
HY-153367
FHD-609BRD9 PROTAC Degrader -
HY-103713
SeclidemstatLSD1 Inhibitor -
HY-145925B
CFT8634BRD9 PROTAC Degrader -
HY-144896
FHT-1015SMARCA4/SMARCA2 ATPase Inhibitor -
HY-149420
BRD7-IN-2BRD7 Inhibitor -
HY-149026
GNE-064SMARCA4/SMARCA2/PBRM1 Inhibtor
Publications Citing Use of MedChemExpress (MCE) BRD-K98645985
More
Customer Validation & Images
-
Flow Cytometry
-
Flow Cytometry
-
In Vivo Efficacy Study
-
Flow Cytometry
-
In Vivo Efficacy Study
Actividad biológica
Descripciòn
IC50 & Target
[1]|
BAF transcriptional repression 2.37 μM (EC50) |
HIV-1 |
In Vitro
BRD-K98645985 (30 μM; 18 hours) treatment shows a 5-fold increase in Bmi1, 2.6-fold increase in Ring1, and 3.3-fold decrease in Fgf4[1].
BRD-K98645985 treatment shows a concentration dependent latency reversal in J-Lat T-cell line models. BRD-K98645985 can be combined with other LRAs to improve reservoir targeting[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
No. CAS 1357647-78-9
-
Appearance Solid
-
Peso molecular 573.73
-
Fòrmula C33H43N5O4
-
Color White to light brown
-
SMILES
O=C(NC1=CC=C(OC[C@H](C)N(CC2=CC=C(C3=NC=CC=C3)C=C2)C[C@H](C)[C@@H](OC)CN(C)C4=O)C4=C1)NC(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nature
2022 Jul;607(7917):135-141. PMID: 35732731
BRD-K98645985 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):135-141. [Abstract]
BRD-K98645985 (BD98;1 μM; 8 days) increased the proportion CD62L+ CD44+CAR-T cells B7-H3 CAR-T.
BRD-K98645985 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):135-141. [Abstract]
BRD-K98645985 (BD98;1 μM; 48 h) and removed the drug, and cultured the cells for 2 days with interleukin-2 (IL-2), promoted the generation of cells with the TCM marker CD62L + CD44+ in OT-I cells.
BRD-K98645985 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):135-141. [Abstract]
BRD-K98645985 (BD98;1 μM; 48 h) activated OT-I cells and then the OT-I T cells were transferred to animals bearing palpable B16-Ova or MC38-Ova tumors. Transient treatment with BD98 improved the ability of OT-I cells to control tumor growth in vivo.
BRD-K98645985 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):135-141. [Abstract]
BRD-K98645985 (BD98;1 μM; 1, 3, 6, 9, 12 days) stimulation with B7-H3-expressing tumor cells (F420 and GL261) in vitro, resulted in a greater expansion of the CAR-T cells derived from T cells transiently.
BRD-K98645985 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):135-141. [Abstract]
BRD-K98645985 (BD98;1 μM; 1, 3, 6, 9, 12 days) generated from activated T cells that displayed markedly enhanced tumor control in F420 tumor-bearing mice.
-
bioRxiv
2026 Apr 22:2026.04.20.719605. PMID: 42079300 -
-
bioRxiv
Activity-assembled nBAF complex mediates rapid immediate early gene transcription by regulating RNA Polymerase II productive elongation. [Abstract]2023: 2023.12 PMID: 38234780
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (174.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.63 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7430 mL | 8.7149 mL | 17.4298 mL | 43.5745 mL |
| 5 mM | 0.3486 mL | 1.7430 mL | 3.4860 mL | 8.7149 mL | |
| 10 mM | 0.1743 mL | 0.8715 mL | 1.7430 mL | 4.3575 mL | |
| 15 mM | 0.1162 mL | 0.5810 mL | 1.1620 mL | 2.9050 mL | |
| 20 mM | 0.0871 mL | 0.4357 mL | 0.8715 mL | 2.1787 mL | |
| 25 mM | 0.0697 mL | 0.3486 mL | 0.6972 mL | 1.7430 mL | |
| 30 mM | 0.0581 mL | 0.2905 mL | 0.5810 mL | 1.4525 mL | |
| 40 mM | 0.0436 mL | 0.2179 mL | 0.4357 mL | 1.0894 mL | |
| 50 mM | 0.0349 mL | 0.1743 mL | 0.3486 mL | 0.8715 mL | |
| 60 mM | 0.0290 mL | 0.1452 mL | 0.2905 mL | 0.7262 mL | |
| 80 mM | 0.0218 mL | 0.1089 mL | 0.2179 mL | 0.5447 mL | |
| 100 mM | 0.0174 mL | 0.0871 mL | 0.1743 mL | 0.4357 mL |
BRD-K98645985 Related Classifications
HY-114268 Related Classifications
Powered by Bioz